Date: 2012-09-14
Type of information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Kaketsuken (Japan) GSK (UK)
Product: cell culture based pandemic flu vaccine co-developed with GlaxoSmithKline (GSK) and using Vivalis’ EB66® cell line
Action mechanism:
Disease: influenza
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: Vivalis has announced the advancement of a human influenza vaccine into Phase III clinical trials being jointly developed by the Chemo-Sero-Therapeutic Research Institute of Japan (“Kaketsuken”), GSK Japan, and GlaxoSmithKline Biologicals (“GSK Bio”).
